NALMEFENE HCL Trademark

Trademark Overview

On Wednesday, March 18, 2026, a trademark application was filed for NALMEFENE HCL with the United States Patent and Trademark Office. The USPTO has given the NALMEFENE HCL trademark a serial number of 99710822. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, March 18, 2026. This trademark is owned by Purdue Pharma L.P.. The NALMEFENE HCL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists
nalmefene hcl

General Information

Serial Number99710822
Word MarkNALMEFENE HCL
Filing DateWednesday, March 18, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, March 18, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the words Nalmefene HCl beneath 5 small squares and three horizontal lines that transition from solid to decreasing shading.
Goods and ServicesPharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 18, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePurdue Pharma L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901
US

Trademark Events

Event DateEvent Description
Wednesday, March 18, 2026NEW APPLICATION ENTERED
Wednesday, March 18, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

nalmefene opioid pharmaceuticals antagonists filled disorders treatment reversal overdose injectable injectors